Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

Third-Party Covid-19-Specific Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients With Covid-19 Infection

The purpsse of this research is to assess the safety and effectiveness of a new experimental treatment for COVID-19 infection. While the infection and virus actually have different names, for the purpose of this consent, we will refer to them both as COVID-19. Specifically, this is the virus that has caused the pandemic that moved across the world in early 2020. You are being offered this experimental treatment because you have tested positive for the COVID-19 virus and have additional reasons to be considered at higher risk for a more serious outcome compared to the average patient who develops this infection.

Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

Recruitment

Summary

Participation Requirements

Description

Tracking Information